Danaher Corporation $DHR Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 5,317.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,103,255 shares of the conglomerate's stock after purchasing an additional 2,064,431 shares during the quarter. Assenagon Asset Management S.A. owned about 0.30% of Danaher worth $465,976,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Retirement Planning Co of New England Inc. bought a new position in Danaher in the 3rd quarter worth about $3,032,000. Mystic Asset Management Inc. bought a new stake in shares of Danaher during the third quarter valued at approximately $4,467,000. RDA Financial Network raised its holdings in shares of Danaher by 166.9% during the third quarter. RDA Financial Network now owns 6,468 shares of the conglomerate's stock valued at $1,433,000 after buying an additional 4,045 shares during the last quarter. Ninety One UK Ltd boosted its position in shares of Danaher by 22.4% during the third quarter. Ninety One UK Ltd now owns 64,880 shares of the conglomerate's stock worth $14,374,000 after buying an additional 11,890 shares during the period. Finally, PFG Private Wealth Management LLC acquired a new position in shares of Danaher during the third quarter worth approximately $1,031,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analyst Upgrades and Downgrades

Several research firms recently commented on DHR. UBS Group began coverage on Danaher in a research report on Wednesday, September 9th. They issued a "buy" rating and a $250.00 target price on the stock. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Guggenheim boosted their price target on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Wells Fargo & Company decreased their price target on Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. Finally, Morgan Stanley raised their price target on Danaher from $220.00 to $240.00 and gave the company an "overweight" rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $235.41.

Danaher Price Performance

NYSE:DHR opened at $231.52 on Friday. The business's 50-day moving average price is $213.55 and its 200 day moving average price is $195.74. The firm has a market cap of $162.76 billion, a P/E ratio of 27.67, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the firm posted $0.77 EPS. The business's revenue for the quarter was up 5.5% on a year-over-year basis. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher's dividend payout ratio is currently 28.42%.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.